We are international
Donate
• about myeloma TEXT SIZE   
treatment options

CITINGS
04.05.06

The IMF is pleased to bring you CITINGS, a quarterly publication featuring the most up-to-date information on research advances and new therapies for the treatment for multiple myeloma. CITINGS provides physicians and other health care professionals with references and Internet links to the most current U.S. and international journal articles, abstracts, and white papers. Each issue presents articles related to new drugs, either as the focus of the study or as part of the discussion of myeloma treatment.

  • Volume III, Issue I, First Quarter 2006: Thalidomide and Revlimid™
    We are pleased to present our first edition of CITINGS for 2006. This quarterly publication features citations to the most up-to-date studies on myeloma treatment. In this issue, we focus on thalidomide and Revlimid™ for the treatment of multiple myeloma. Inside you will find references to the latest published journal articles on both thalidomide and Revlimid from the first quarter of this year.

  • Volume II, Issue IV, Fall 2005: Thalidomide and Revlimid™
    In this issue we are continuing our series focusing specifically on publications referring to thalidomide and its analogues. In addition to our usual summary of publications found in scientific journals, we have added to this issue summaries of all the major papers presented at the three large hematology meetings that have taken place so far in 2005. In it you will find summaries from:
  1. the 10th International Myeloma Workshop held this year in Sydney, Australia from April 10 - 14,
  2. the American Society of Clinical Oncology (ASCO) meeting held in Orlando from May 14 - 17 and,
  3. the 10th Congress of the European Hematology Association held in Stockholm, Sweden, from June 2 - 5.
  • Special Edition ASCO 2005: Velcade® (bortezomib) Issue
    The International Myeloma Foundation(IMF) is pleased to present our first VELCADE® (bortezomib)-focused edition of CITINGS for 2005, a relatively recent publication featuring the most up-to-date information on new therapies for multiple myeloma. VELCADE is the first of a new class of drugs called proteasome inhibitors. Because it is a new type of drug, VELCADE represents a new treatment option for patients who have relapsed on other standard therapies. This issue of CITINGS has been prepared by the IMF to correspond with the annual meeting of the American Society of Clinical Oncology (ASCO) in Orlando, Florida. In this issue, readers will find three key resources related to VELCADE: 1) a list of selected bortezomib data presented at the ASCO meeting, along with dates and times of each presentation, 2) a list of selected bortezomib-related studies presented at the 10th International MyelomaWorkshop in Sydney, Australia from April 10th- 14th 2005, and 3) references to the latest published studies on bortezomib.


  • Volume II, Issue III: Spring 2005: Revlimid™
    The IMF is pleased to present our third issue of CITINGS for 2005. In this issue we are continuing our series focusing specifically on publications referring to Revlimid™.


  • Volume II, Issue II: Spring 2005: Thalidomide
    The IMF is pleased to present our second issue of CITINGS for 2005. In this issue we are continuing our series focusing specifically on publications referring to thalidomide.

  • Volume II, Issue I, Winter 2005: Kyphoplasty
    The IMF is pleased to present our first issue of CITINGS focused on kyphoplasty. Kyphoplasty is an innovative, minimally invasive surgical procedure for treating osteoporotic and cancer-related fractures in which an orthopedic balloon is inserted into the fractured bone in order to restore the bone to its pre-fracture height, and a cement-like material is then injected directly into the void created by the balloon. The procedure shows great promise in the treatment of painful osteoporotic or cancer-related vertebral compression fractures.

  • Special Issue ASH 2004: Velcade® (bortezomib) Issue
    This issue of CITINGS has been prepared by the IMF to correspond with the 46th American Society of Hematology (ASH) annual meeting in San Diego, California. In this issue, readers will find three key resources related to VELCADE: 1) a list of selected bortezomib data being presented at the ASH meeting, along with dates and times of each presentation, 2) a list of selected bortezomib-related studies presented at the European Hematology Association meeting, and 3) references to the latest published studies on bortezomib.

  • Special Issue ASH 2004: Thalidomide and Revlimid™
    In this edition, we continue our focus on thalidomide and Revlimid™ (CC-5013) and highlight data presentations taking place at the American Society of Hematology (ASH) Annual Meeting. The IMF has selected key presentations and has listed the date and time of each to facilitate your scheduling needs.

  • Volume I, Issue II, Summer 2004
    Our second issue continues our focus on thalidomide and Revlimid™ for the treatment of myeloma.

  • Volume I, Issue I, Spring 2004
    Thalidomide and Revlimid™ Issue


 related articles